JNJ

227.84

+1.49%↑

ISRG

522.43

-0.51%↓

ABT

105.93

-2.09%↓

MDT

100.66

-0.05%↓

133.89

-1.33%↓

JNJ

227.84

+1.49%↑

ISRG

522.43

-0.51%↓

ABT

105.93

-2.09%↓

MDT

100.66

-0.05%↓

133.89

-1.33%↓

JNJ

227.84

+1.49%↑

ISRG

522.43

-0.51%↓

ABT

105.93

-2.09%↓

MDT

100.66

-0.05%↓

133.89

-1.33%↓

JNJ

227.84

+1.49%↑

ISRG

522.43

-0.51%↓

ABT

105.93

-2.09%↓

MDT

100.66

-0.05%↓

133.89

-1.33%↓

JNJ

227.84

+1.49%↑

ISRG

522.43

-0.51%↓

ABT

105.93

-2.09%↓

MDT

100.66

-0.05%↓

133.89

-1.33%↓

Kodu・Aktsiate loetelu・Lexicon Pharmaceuticals Inc

Lexicon Pharmaceuticals Inc

Suletud

SektorTervishoid

1.5 -11.76

Osta Müü

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

1.49

Max

1.7

Põhinäitajad
By Trading Economics
Sissetulek	-16M -13M
Müük	-15M 14M
Kasumimarginaal	-90.037
Töötajad	103
EBITDA	-16M -10M

Soovitused
By TipRanks
Soovitused	Tugev "osta" hinnang
12 kuu keskmine prognoos	+156.69% upside

Dividendid
By Dow Jones
Järgmine tulemuste avaldamine	5. märts 2026

Turustatistika
By TradingEconomics
Turukapital	76M 571M
Eelmine avamishind	13.26
Eelmine sulgemishind	1.5

Uudiste sentiment

By Acuity

50%

133 / 352 Pingereas Healthcare

Tehniline skoor

By Trading Central

Kindlus

Bearish Evidence

0.6863 / 0.72 Toetus ja vastupanu

Lexicon Pharmaceuticals Inc Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

28. jaan 2026, 23:51 UTC

Tulu

Correction to Samsung Fourth-Quarter Net Profit Article

28. jaan 2026, 23:49 UTC

Kuumad aktsiad

Stocks to Watch: Meta, IBM, Las Vegas Sands, Whirlpool

28. jaan 2026, 23:19 UTC

Tulu

Samsung's Fourth-Quarter Net Profit Beats Consensus

28. jaan 2026, 22:43 UTC

Tulu

Waste Management Logs Higher 4Q Profit as Revenue Rises

29. jaan 2026, 00:00 UTC

Omandamised, ülevõtmised, äriostud

Diller's Overture Came Before Warner Unveiled Split Plans, Source Says -- WSJ

29. jaan 2026, 00:00 UTC

Omandamised, ülevõtmised, äriostud

Warner Says CNN Wasn't and Isn't for Sale -- WSJ

29. jaan 2026, 00:00 UTC

Omandamised, ülevõtmised, äriostud

Barry Diller Told Warner Bros. Discovery He Is Interested in Buying CNN -- WSJ

29. jaan 2026, 00:00 UTC

Omandamised, ülevõtmised, äriostud

Barry Diller Approached Warner Bros. Discovery Last Year About Buying CNN, Sources Say -- WSJ

28. jaan 2026, 23:49 UTC

Market Talk

Nikkei May Rise as Weaker Yen Supports Earnings Hopes -- Market Talk

28. jaan 2026, 23:30 UTC

Market Talk

Tesla to Use Car Factory for Robot Aims -- Market Talk

28. jaan 2026, 23:28 UTC

Tulu

Microsoft's Earnings Surge, Elevated by Cloud Business -- 3rd Update

28. jaan 2026, 23:26 UTC

Tulu

Meta Reports Record Sales, Massive Spending Hike on AI Buildout -- 2nd Update

28. jaan 2026, 23:21 UTC

Tulu

Microsoft Stock Falls Despite Earnings Beat. Cloud Growth Slowed Slightly. -- Barrons.com

28. jaan 2026, 23:18 UTC

Tulu

Omandamised, ülevõtmised, äriostud

Tesla to Invest $2 Billion in Elon Musk's xAI -- Update

28. jaan 2026, 22:58 UTC

Tulu

Tesla to Invest $2 Billion in Elon Musk's xAI -- Update

28. jaan 2026, 22:48 UTC

Market Talk

Woodside Energy Has Form With Conservative Production Guidance -- Market Talk

28. jaan 2026, 22:45 UTC

Tulu

Samsung Electronics 2025 Net KRW45.207T Vs. Net KRW34.451T >005930.SE

28. jaan 2026, 22:44 UTC

Tulu

Samsung Electronics 2025 Oper Pft KRW43.601T Vs. Pft KRW32.726T >005930.SE

28. jaan 2026, 22:43 UTC

Tulu

Samsung Electronics 2025 Rev KRW333.606T Vs. KRW300.871T >005930.SE

28. jaan 2026, 22:41 UTC

Tulu

Kuumad aktsiad

Earnings in Focus Wednesday: Microsoft, Tesla, Meta, Starbucks -- WSJ

28. jaan 2026, 22:41 UTC

Market Talk

Rising AUD Typically Sees Australian Stocks Outperform -- Market Talk

28. jaan 2026, 22:41 UTC

Tulu

Meta Stock Rises on Strong Earnings. Expenses Are Mounting. -- Barrons.com

28. jaan 2026, 22:40 UTC

Tulu

Samsung Electronics 4Q Net Profit Beat FactSet-Compiled Consensus

28. jaan 2026, 22:39 UTC

Tulu

Samsung Electronics 4Q Net KRW19.642T Vs. Net KRW7.754T >005930.SE

28. jaan 2026, 22:38 UTC

Tulu

Samsung Electronics 4Q Oper Pft KRW20.074T Vs. Pft KRW6.493T >005930.SE

28. jaan 2026, 22:37 UTC

Tulu

Samsung Electronics 4Q Rev KRW93.837T Vs. KRW75.788T >005930.SE

28. jaan 2026, 22:35 UTC

Tulu

Microsoft Stock Falls Despite Earnings Beat. Cloud Growth Slowed Slightly. -- Barrons.com

28. jaan 2026, 22:26 UTC

Market Talk

Tulu

Meta's Rising CapEx is Fueled by High Pay for AI Workers -- Market Talk

28. jaan 2026, 22:20 UTC

Market Talk

Global Equities Roundup: Market Talk

28. jaan 2026, 22:20 UTC

Market Talk

Woodside Energy's Oil Assets Blamed for Guidance Miss -- Market Talk

Võrdlus sarnastega

Hinnamuutus

Lexicon Pharmaceuticals Inc Prognoos

Hinnasiht

By TipRanks

156.69% tõus

12 kuu keskmine prognoos

Keskmine 4.03 USD 156.69%

Kõrge 6 USD

Madal 2.1 USD

Põhineb 3 Wall Streeti analüütiku instrumendi Lexicon Pharmaceuticals Inc 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Tugev "osta" hinnang

3 ratings

Osta

Hoia

Müü

Põhineb 3 analüütiku instrumendi Lexicon Pharmaceuticals Inc aktsia reitingul - viimase 3 kuu andmed.

Tehniline skoor

By Trading Central

0.6863 / 0.72Toetus ja vastupanu

Recent bearish events outweigh bullish events.

All events are bullish.

There is one bearish event.

Sentiment

By Acuity

133 / 352 Pingereas Tervishoid

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

Ettevõttest Lexicon Pharmaceuticals Inc

Lexicon Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical products. Its orally-delivered small molecule drug candidates under development comprise Sotagliflozin that completed Phase III clinical trials for the for the treatment of heart failure and type 1 diabetes; and LX9211, which is in Phase II clinical development for the treatment of neuropathic pain and LX2761, which is in Phase I clinical development for gastrointestinal tract. Lexicon Pharmaceuticals, Inc. has strategic collaboration and license agreements with Bristol-Myers Squibb Company and Genentech, Inc. The company was incorporated in 1995 and is headquartered in The Woodlands, Texas.